Literature DB >> 32953993

SARS-CoV-2 and EBV coinfection.

Francisco Javier García-Martínez1, Ester Moreno-Artero1, Sandra Jahnke2.   

Abstract

Entities:  

Year:  2020        PMID: 32953993      PMCID: PMC7486856          DOI: 10.1016/j.medcle.2020.06.010

Source DB:  PubMed          Journal:  Med Clin (Engl Ed)        ISSN: 2387-0206


× No keyword cloud information.
Dear Editor: Co-infection by two or more pathogens is a common finding in infectology. However, the simultaneous infection by two viruses such as the Epstein-Barr virus (EBV) and the severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) has not been reported to date. In the context of a coronavirus pandemic (COVID-19), any infectious clinical condition is suspected of COVID-19. The lockdown of the population sometimes makes us forget that other pathogens can also be transmitted and manifest themselves. A 19-year-old French woman, with no relevant history, came to the emergency department with a two-day history of fever, bilateral eyelid oedema, and right hemifacial swelling. In addition to the skin manifestations, the physical examination showed bilateral cervical lymphadenopathy, non-suppurative pharyngotonsillitis, and splenomegaly. The results of the lab tests and the serological study are summarized in Table 1 . The presence of SARS-CoV-2 RNA was detected in the reverse transcriptase polymerase chain reaction (RT-PCR) of the sample obtained by oronasopharyngeal swab. The presence of EBV was also detected by PCR in blood (4700 copies/mL) and plasma (9600 copies/mL). The mumps virus could not be detected in the saliva cell culture. An anteroposterior chest radiograph and a computed tomography (CT) scan of the chest and abdomen showed splenomegaly (diameter greater than 16 cm) in the absence of pulmonary pathological findings. With a diagnosis of infectious mononucleosis (IM) mimicking mumps and asymptomatic Covid-19, in the absence of other complications, exclusively symptomatic and supportive treatment was recommended. The patient experienced a significant clinical improvement after two weeks of follow-up.
Table 1

Lab and serological results.

Lab parametersUnitsResultNormal values
Leukocytes109cel/L,11,83,89–9,23
Neutrophils109cel/L (%)1,58 (13)1.49−4.67 (45−75)
Lymphocytes109cel/L (%)8.46 (71)1.24−3.05 (20−50)
Monocytes109cel/L (%)1.61 (13.6)0.29−0.72 (2−9)
TransaminasesUI/L
Aspartate transaminase239≤32
Alanine transaminase264≤33
Gamma-glutamyltransferase89≤40
Alkaline phosphataseUI/L30635−104
Ferritinng/mL243,815−150
D-dimerng/mL2950150−500
C-reactive proteinmg/dL0,95≤0.5
Lab and serological results. IM is a clinical syndrome characterized by fever, weakness, bilateral cervical lymphadenopathy, pharyngotonsillitis, and splenomegaly. The pathogen responsible for most cases is herpesvirus 4 or EBV and to a lesser extent, cytomegalovirus (CMV). Other pathogens that cause mononucleosis syndromes are hepatitis viruses, coxsackie A, parvovirus B-19, and HIV, but not coronaviruses. The patient had common laboratory abnormalities in IM, such as lymphocytosis or hypertransaminasemia, although abnormally high ferritin or D-dimer lab values were simultaneously observed, typical of COVID-19. Although fever is common in both COVID-19 and IM, splenomegaly and cervical lymphadenopathy are not common symptoms of SARS-CoV-2 infection. Mumps or parotitis is not common in Spain since the introduction of the MMR vaccine (measles, mumps and rubella) in the vaccination schedule in 1981, although outbreaks have been reported in recent years in universities and student residences in young people born between the years 1990 and 2000. We were able to verify that the patient was immunized in France with the MMR vaccine at 12 and 16 months in 2002. The different clinical manifestations of IM include bilateral eyelid oedema and facial swelling mimicking mumps. In this case, and in the absence of the virus in the saliva sample, we interpret the elevation of the anti-mumps IgM antibody titre as a false positive. This serological cross reaction has been previously reported and attributed to EBV. On the contrary, serological cross-reaction with measles is not so common in EBV, so we cannot rule out that SARS-CoV-2 was also involved in this case. SARS-CoV-2 shares morphostructural similarities with paramyxoviruses and they all express class I membrane fusion proteins. Our patient did not present pulmonary abnormalities in the CT scan performed, showing exclusively laboratory abnormalities attributable to COVID-19, despite the immunosuppression that IM can induce. Some authors suggest that the stimulation or training of the innate immune response induced by other infections and vaccines would favour the early synthesis of interferon and Toll-like receptors, which could explain the benign course of COVID-19 infection in children and young adults. In conclusion, we consider it important not to ignore other pathogens in febrile syndromes during this pandemic, not being tempted to attribute new, previously unreported clinical manifestations, to SARS-CoV-2.

Conflicts of interest

The authors declare no conflict of interest.
  5 in total

1.  Etiology of mumps-like illnesses in children and adolescents vaccinated for measles, mumps, and rubella.

Authors:  Irja Davidkin; Sari Jokinen; Anja Paananen; Pauli Leinikki; Heikki Peltola
Journal:  J Infect Dis       Date:  2005-01-19       Impact factor: 5.226

2.  Shift within age-groups of mumps incidence, hospitalizations and severe complications in a highly vaccinated population. Spain, 1998-2014.

Authors:  Noemí López-Perea; Josefa Masa-Calles; María de Viarce Torres de Mier; Aurora Fernández-García; Juan E Echevarría; Fernando De Ory; María Victoria Martínez de Aragón
Journal:  Vaccine       Date:  2017-07-04       Impact factor: 3.641

Review 3.  Common Features of Enveloped Viruses and Implications for Immunogen Design for Next-Generation Vaccines.

Authors:  Felix A Rey; Shee-Mei Lok
Journal:  Cell       Date:  2018-03-08       Impact factor: 41.582

Review 4.  Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection.

Authors:  Mihai G Netea; Evangelos J Giamarellos-Bourboulis; Jorge Domínguez-Andrés; Nigel Curtis; Reinout van Crevel; Frank L van de Veerdonk; Marc Bonten
Journal:  Cell       Date:  2020-05-04       Impact factor: 41.582

5.  Clinical Characteristics of Coronavirus Disease 2019 in China.

Authors:  Wei-Jie Guan; Zheng-Yi Ni; Yu Hu; Wen-Hua Liang; Chun-Quan Ou; Jian-Xing He; Lei Liu; Hong Shan; Chun-Liang Lei; David S C Hui; Bin Du; Lan-Juan Li; Guang Zeng; Kwok-Yung Yuen; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Ping-Yan Chen; Jie Xiang; Shi-Yue Li; Jin-Lin Wang; Zi-Jing Liang; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Nan-Shan Zhong
Journal:  N Engl J Med       Date:  2020-02-28       Impact factor: 91.245

  5 in total
  4 in total

1.  A Case Found to Be Severe Acute Respiratory Syndrome Coronavirus 2 Positive Immediately Before Hospitalization for Infectious Mononucleosis.

Authors:  Ryo Kawaura; Ryo Utakata; Daikei Kondo; Takanori Wakaoka; Masami Ohnishi
Journal:  Cureus       Date:  2021-11-08

Review 2.  Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms.

Authors:  Amy D Proal; Michael B VanElzakker
Journal:  Front Microbiol       Date:  2021-06-23       Impact factor: 5.640

3.  In vitro Studies and Clinical Observations Imply a Synergistic Effect Between Epstein-Barr Virus and Dengue Virus Infection.

Authors:  Xiao-Mei Deng; Ling-Zhai Zhao; Xue-Ying Liang; Dan Li; Lei Yu; Fu-Chun Zhang; Hua Zhang; Zhong-Yu Liu; Pei Xu
Journal:  Front Microbiol       Date:  2021-06-18       Impact factor: 5.640

4.  Coinfection with severe acute respiratory syndrome coronavirus-2 and other respiratory viruses at a tertiary hospital in Korea.

Authors:  Zehwan Kim; Jong Ho Lee
Journal:  J Clin Lab Anal       Date:  2021-07-17       Impact factor: 2.352

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.